Next Science Limited
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides woun… Read more
Next Science Limited (NXSCF) - Total Liabilities
Latest total liabilities as of June 2025: $10.02 Million USD
Based on the latest financial reports, Next Science Limited (NXSCF) has total liabilities worth $10.02 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Next Science Limited - Total Liabilities Trend (2016–2024)
This chart illustrates how Next Science Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Next Science Limited Competitors by Total Liabilities
The table below lists competitors of Next Science Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Medadvisor Ltd
AU:MDR
|
Australia | AU$41.46 Million |
|
Canoo Inc
NASDAQ:GOEV
|
USA | $301.33 Million |
|
Reallusion Inc.
TWO:6882
|
Taiwan | NT$64.57 Million |
|
Lux Metals Corp.
F:GP80
|
Germany | €184.93K |
|
Austem Company Ltd
KQ:031510
|
Korea | ₩61.18 Billion |
|
United Lithium Corp
OTCQX:ULTHF
|
USA | $369.16K |
|
Nidaros Sparebank
OL:NISB
|
Norway | Nkr4.41 Billion |
|
Dev Information Technology Limited
NSE:DEVIT
|
India | ₹782.38 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Next Science Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -17.98 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Next Science Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Next Science Limited (2016–2024)
The table below shows the annual total liabilities of Next Science Limited from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.77 Million | +13.63% |
| 2023-12-31 | $5.08 Million | -22.14% |
| 2022-12-31 | $6.52 Million | +121.78% |
| 2021-12-31 | $2.94 Million | -37.37% |
| 2020-12-31 | $4.70 Million | +40.70% |
| 2019-12-31 | $3.34 Million | +36.73% |
| 2018-12-31 | $2.44 Million | +336.36% |
| 2017-12-31 | $559.46K | +125.39% |
| 2016-12-31 | $248.22K | -- |